Lecanemab in France: The Times They Are a-Changin’?
Revue Neurologique. 2025-10-01; :
DOI: 10.1016/j.neurol.2025.10.002
Lire sur PubMed
https://www.bordeaux-neurocampus.fr/12263
1. Rev Neurol (Paris). 2025 Oct 23:S0035-3787(25)00618-6. doi:
10.1016/j.neurol.2025.10.002. Online ahead of print.
Lecanemab in France: The Times They Are a-Changin’?
Villain N(1), Planche V(2), Garnier-Crussard A(3), Wallon D(4).
Author information:
(1)Inserm U1127, CNRS 7225, Institut du Cerveau – ICM, Sorbonne Université,
75013 Paris, France; Department of Neurology, Hospital La Pitié-Salpêtrière,
Institute of Memory and Alzheimer’s Disease, Sorbonne Université, AP-HP, 75013
Paris, France. Electronic address: .
(2)UMR 5293, CNRS, Institut des Maladies Neurodégénératives, Bordeaux
University, Bordeaux, France; Pôle de Neurosciences Cliniques, Centre Mémoire de
Ressources et de Recherche, CHU de Bordeaux, Bordeaux, France.
(3)Clinical and Research Memory Centre of Lyon, Charpennes Hospital, Hospices
Civils de Lyon, Lyon Institute For Aging, Villeurbanne, France; CNRS, Inserm,
Centre de Recherche en Neurosciences de Lyon CRNL U1028 UMR5292, Université
Claude-Bernard Lyon 1, 69500 Bron, France.
(4)Inserm U1245 Department of Neurology and CNRMAJ, University of
Rouen-Normandie, CHU of Rouen, 76000 Rouen, France.
DOI: 10.1016/j.neurol.2025.10.002
PMID: 41136273
Conflict of interest statement: Disclosure of interest Independent of this work,
NV received research support from Fondation Bettencourt-Schueller, Fondation
Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation
Claude Pompidou, Fondation Alzheimer, Banque Publique d’Investissement, Lions
Club Alzheimer and Fondation pour la Recherche sur l’Alzheimer; travel grant
from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare
SAS; is an unpaid local principal investigator or sub-investigator in
NCT05531526 (AR1001, AriBio), NCT06079190 (AL101, GSK), NCT04241068 and
NCT05310071 (aducanumab, Biogen), NCT05399888 (BIIB080, Biogen), NCT03352557
(gosuranemab, Biogen), NCT04592341 (gantenerumab, Roche), NCT03887455
(lecanemab, Eisai), NCT03828747 and NCT03289143 (semorinemab, Roche),
NCT04619420 (JNJ-63733657, Janssen – Johnson & Johnson), NCT06544616
(JNJ-64042056, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector),
NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396
and NCT04777409 (semaglutide, Novo Nordisk), NCT05469360 (NIO752, Novartis),
NCT06647498 (remternetug, Washington University School of Medicine); is the
unpaid French national coordinator in NCT05564169 (VHB937, Novartis); has given
unpaid lectures in symposia organised by Eisai and the Servier Foundation; has
been an unpaid expert for Janssen – Johnson & Johnson, Eli-Lilly, Novartis.
During the past three years, V.P. was a local unpaid investigator or
sub-investigator for clinical trials granted by Novo Nordisk, Biogen, Janssen,
and Alector; served as a consultant for Motac Neuroscience Ltd, outside the
submitted work. A.G.-C. is an unpaid sub-investigator or local principal
investigator for clinical trials and studies sponsored by UCB Pharma, Biogen,
TauRx Therapeutics, Roche, Novo Nordisk, Alzheon, Medesis Pharma,
GlaxoSmithKline, and participated in studies granted by Roche, Lilly and Eisai;
declares he has not received any personal funding and has not participated in
any remunerated activities. During the past five years, D.W. was an unpaid local
investigator or sub-investigator for clinical trials and studies sponsored by
Biogen, Roche, Alzheon, Karuna, GlaxoSmithKline; served as an expert consultant
for Lilly and Eisai; declares he has not received any personal funding and has
not participated in any remunerated activities.